JP2009537550A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537550A5
JP2009537550A5 JP2009511089A JP2009511089A JP2009537550A5 JP 2009537550 A5 JP2009537550 A5 JP 2009537550A5 JP 2009511089 A JP2009511089 A JP 2009511089A JP 2009511089 A JP2009511089 A JP 2009511089A JP 2009537550 A5 JP2009537550 A5 JP 2009537550A5
Authority
JP
Japan
Prior art keywords
ethoxy
pharmaceutical composition
cyclosporine
cyclosporin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009511089A
Other languages
English (en)
Japanese (ja)
Other versions
JP5377293B2 (ja
JP2009537550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/011919 external-priority patent/WO2007136759A2/en
Publication of JP2009537550A publication Critical patent/JP2009537550A/ja
Publication of JP2009537550A5 publication Critical patent/JP2009537550A5/ja
Application granted granted Critical
Publication of JP5377293B2 publication Critical patent/JP5377293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009511089A 2006-05-19 2007-05-18 眼疾患の治療及び予防方法 Active JP5377293B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80220806P 2006-05-19 2006-05-19
US60/802,208 2006-05-19
PCT/US2007/011919 WO2007136759A2 (en) 2006-05-19 2007-05-18 Method for the treatment and prevention of ocular disorders

Publications (3)

Publication Number Publication Date
JP2009537550A JP2009537550A (ja) 2009-10-29
JP2009537550A5 true JP2009537550A5 (enExample) 2010-07-01
JP5377293B2 JP5377293B2 (ja) 2013-12-25

Family

ID=37814449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511089A Active JP5377293B2 (ja) 2006-05-19 2007-05-18 眼疾患の治療及び予防方法

Country Status (12)

Country Link
US (2) US8188052B2 (enExample)
EP (1) EP2023918B1 (enExample)
JP (1) JP5377293B2 (enExample)
CN (1) CN101511357B (enExample)
AT (1) ATE502633T1 (enExample)
AU (1) AU2007254148B2 (enExample)
CA (1) CA2652662C (enExample)
DE (1) DE602007013391D1 (enExample)
DK (1) DK2023918T3 (enExample)
ES (1) ES2361635T3 (enExample)
WO (1) WO2007136759A2 (enExample)
ZA (1) ZA200810113B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
CA2623864C (en) * 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
CN105169369B (zh) 2005-09-30 2019-10-18 中美华世通生物医药科技（武汉）有限公司 治疗和预防丙型肝炎感染的方法和药物组合物
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CN102869367A (zh) * 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
MX2013004062A (es) * 2010-10-12 2013-07-22 Allergan Inc Analogos de ciclosporina.
RU2013119869A (ru) * 2010-10-12 2014-11-20 Аллерган, Инк. Аналоги циклоспорина
CN103533962B (zh) * 2011-03-14 2018-05-18 药品配送方案有限公司 一种眼用组合物
US10429712B2 (en) 2012-04-20 2019-10-01 View, Inc. Angled bus bar
CA2874548A1 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
CA2915525A1 (en) 2013-06-18 2014-12-24 View, Inc. Electrochromic devices on non-rectangular shapes
CN107430118A (zh) * 2013-06-27 2017-12-01 广东盛泽康华生物医药有限公司 对自身免疫状况的分类与管理的方法与仪器
MX364310B (es) 2013-11-05 2019-04-22 Gustavo A Garcia Sanchez Método para preparar una formulación inmunosupresora.
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
TWI675851B (zh) * 2015-12-14 2019-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其用途
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
US20200366476A1 (en) * 2019-05-17 2020-11-19 Panasonic Avionics Corporation Transient key negotiation for passenger accessible peripherals
CA3152922A1 (en) * 2019-10-12 2021-04-15 Michael Peel Treatment and prevention of nephrotoxin-induced kidney injuries
CN111920940B (zh) * 2020-09-16 2022-04-05 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
KR20220158760A (ko) * 2020-03-26 2022-12-01 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 사이클로필린 저해제 및 그 용도
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
WO2022115681A2 (en) * 2020-11-30 2022-06-02 Romeg Therapeutics Llc Methods and compositions for oral pilocarpine liquid
KR20260018851A (ko) * 2023-06-02 2026-02-09 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 사이클로필린 저해제 및 그 용도

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
DE69124459T3 (de) 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
AU683049B2 (en) 1993-03-31 1997-10-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Cholestasis ameliorant
US5846964A (en) 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
NZ315324A (en) 1995-07-17 1999-10-28 Chem Ag C Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
WO1999065933A1 (en) 1998-06-12 1999-12-23 C-Chem Ag Novel cyclosporins
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
USRE40987E1 (en) 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6521595B1 (en) 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
CZ303213B6 (cs) 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
CN1984670A (zh) 2004-07-13 2007-06-20 诺瓦提斯公司 治疗阿尔茨海默病的环孢菌素
JP2008506648A (ja) 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト Ｃ型肝炎（ｈｃｖ）処置のためのシクロスポリンとペグ化インターフェロンの組合せ剤の使用
WO2006039163A2 (en) * 2004-09-29 2006-04-13 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
PT1793844E (pt) 2004-10-01 2011-03-10 Debiopharm Sa Utilização de [d-meala]3-[etval]4-csa para o tratamento de infecção causada pelo vírus da hepatite c
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
RU2007128098A (ru) 2004-12-23 2009-01-27 Новартис АГ (CH) Соединения для лечения инфекций, вызываемых вирусами семейства flaviviridae
US7897565B2 (en) 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment
CN105169369B (zh) 2005-09-30 2019-10-18 中美华世通生物医药科技（武汉）有限公司 治疗和预防丙型肝炎感染的方法和药物组合物
CA2623864C (en) 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
WO2009148615A1 (en) 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
AU2010203660A1 (en) 2009-01-07 2011-07-28 Scynexis, Inc Combination of a cyclosporine derivative and nucleosides for treating HCV
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽

Similar Documents

Publication Publication Date Title
JP2009537550A5 (enExample)
JP2008514732A5 (enExample)
KR102279999B1 (ko) 선택적 에스트로겐 수용체 분해제로서의 벤조티오펜 유도체 및 그의 조성물
ES2540561T3 (es) N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
ES2654615T3 (es) Compuestos de carbamato para el tratamiento del trastorno bipolar
ES2521672T3 (es) Formulaciones farmacéuticas para el tratamiento del cáncer
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2009504763A5 (enExample)
JP2014508804A5 (enExample)
JP2015512860A5 (enExample)
JP2012519691A5 (enExample)
JP2007520452A5 (enExample)
ES2748974T3 (es) Inhibidores de la polimerasa del virus de la hepatitis C
AU2017231817A1 (en) Elimination of hepatitis B virus with antiviral agents
JP2013525318A5 (enExample)
WO2014182643A2 (en) Methods for treating hcv infection
JP2007505931A5 (enExample)
WO2010005580A3 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
RU2013152626A (ru) ХИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ОПОСРЕДУЕМЫХ Ape1
AU2019355218A1 (en) Monomer and multimeric anti-HBV agents
JP2012524110A5 (enExample)
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
JP2010514733A5 (enExample)
JP2003520208A5 (enExample)
JP2016523830A5 (enExample)